SCHEMBL6071964

SCHEMBL6071964

CCOc1cc2c(c3c1OC(C)(C)C3)C(c1ccc(C(=O)OC)c(NCc3ccccc3OC)c1)=NC(C)(C)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.38
MAPT P10636 6/20 0.37
TP53 P04637 4/20 0.37
LMNA P02545 2/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
RAB9A P51151 2/20 0.37
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ASPH Q12797 1/20 0.37
KDM8 Q8N371 1/20 0.37
KMT2A Q03164 3/20 0.34
ABL1 P00519 1/20 0.34
SRC P12931 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 2/20 0.33
POLB P06746 1/20 0.33
USP2 O75604 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6072050 0.94 KDM4E (0.42) TSHRMAPTTP53LMNAALDH1A1
SCHEMBL6071890 0.91 POLB (0.36) MAPTLMNAALDH1A1HPGDRAB9A
SCHEMBL6071796 0.89 ALDH1A1 (0.35) MAPTTP53LMNAALDH1A1HPGD
SCHEMBL6071599 0.89 TDP1 (0.32)
SCHEMBL6071784 0.89 MAPT (0.40) TSHRMAPTTP53LMNAALDH1A1
Hydrochloric Acid SCHEMBL6072515 0.88 TDP1 (0.32)
SCHEMBL6072340 0.87 MAPT (0.35) TSHRMAPTLMNAALDH1A1RAB9A
SCHEMBL6072420 0.87 MAPT (0.35) MAPTTP53LMNAALDH1A1KDM4E
SCHEMBL6072274 0.87 HDAC8 (0.37)
SCHEMBL6072104 0.87 FFAR4 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106048-A1 Furoisoquinoline derivative and use thereof PASCALI, PETROS P. (CY) 2006-05-18 US disclosed
EP-1541576-A1 FUROISOQUINOLINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106048-A1 Furoisoquinoline derivative and use thereof PDE3B, PDE2A, PDE3A TSHR 629/4885MAPT 4861/4885TP53 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.